EGFR and non-small cell lung carcinoma: In the case of advanced non-small cell lung cancer, ctDNA has been extensively explored for genotyping of EGFR. Due to a strong correlation between EGFR activating mutations and the efficacy of EGFR tyrosine kinase inhibitors (EGFR-TKIs)9, 10, the detection of mutations is indispensable for therapeutic decision making.